KR101581611B1 - 정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물 - Google Patents

정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물 Download PDF

Info

Publication number
KR101581611B1
KR101581611B1 KR1020147032836A KR20147032836A KR101581611B1 KR 101581611 B1 KR101581611 B1 KR 101581611B1 KR 1020147032836 A KR1020147032836 A KR 1020147032836A KR 20147032836 A KR20147032836 A KR 20147032836A KR 101581611 B1 KR101581611 B1 KR 101581611B1
Authority
KR
South Korea
Prior art keywords
melatonin
memantine
composition
weight
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147032836A
Other languages
English (en)
Korean (ko)
Other versions
KR20150005999A (ko
Inventor
마가리타 알렉세예브나 모로조바
알란 게오르비치 베니아쉬빌리
막심 에두아르도비치 자폴스키
Original Assignee
엘티디 "발렌타-인텔렉트"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘티디 "발렌타-인텔렉트" filed Critical 엘티디 "발렌타-인텔렉트"
Publication of KR20150005999A publication Critical patent/KR20150005999A/ko
Application granted granted Critical
Publication of KR101581611B1 publication Critical patent/KR101581611B1/ko
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147032836A 2012-05-24 2012-10-31 정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물 Ceased KR101581611B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012121410/15A RU2488388C1 (ru) 2012-05-24 2012-05-24 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
RU2012121410 2012-05-24
PCT/RU2012/000888 WO2013176567A1 (ru) 2012-05-24 2012-10-31 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Publications (2)

Publication Number Publication Date
KR20150005999A KR20150005999A (ko) 2015-01-15
KR101581611B1 true KR101581611B1 (ko) 2015-12-31

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147032836A Ceased KR101581611B1 (ko) 2012-05-24 2012-10-31 정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물

Country Status (14)

Country Link
US (1) US20150157604A1 (https=)
EP (1) EP2857011A4 (https=)
JP (1) JP5864819B2 (https=)
KR (1) KR101581611B1 (https=)
CN (1) CN104334166A (https=)
AU (1) AU2012380583B2 (https=)
CA (1) CA2873891C (https=)
EA (1) EA201400973A1 (https=)
HK (1) HK1205467A1 (https=)
IL (1) IL235852A0 (https=)
IN (1) IN2014DN09940A (https=)
RU (1) RU2488388C1 (https=)
UA (1) UA112352C2 (https=)
WO (1) WO2013176567A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (ru) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
US10265497B2 (en) 2015-11-24 2019-04-23 Massachusetts Institute Of Technology Systems and methods for treating dementia
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
UA123552C2 (uk) * 2016-06-29 2021-04-21 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція, що містить комбінацію мемантину і мелатоніну
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
JP6830156B2 (ja) 2016-10-31 2021-02-17 ニューリム・ファーマシューティカルズ・リミテッドNeurim Pharmaceuticals Ltd. メラトニンミニタブレットおよびその製造方法
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
KR20250153860A (ko) 2016-11-17 2025-10-27 코그니토 쎄라퓨틱스, 인코포레이티드 시각 자극을 통한 신경 자극 방법 및 시스템
KR102706443B1 (ko) 2017-10-10 2024-09-11 메사추세츠 인스티튜트 오브 테크놀로지 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
US10960225B2 (en) * 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204259A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
PT1569724E (pt) 2002-10-30 2009-04-03 Asat Ag Applied Science & Tech Formulações contendo melatonina, ginkgo biloba e biotina
RU2268737C2 (ru) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
CA2569015A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
MY148806A (en) * 2005-04-04 2013-05-31 Takeda Pharmaceutical Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia
CN1709230A (zh) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚分散片及其制备方法
RU2294741C1 (ru) 2005-08-08 2007-03-10 Рина Михайловна Заславская Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией
MX2008014840A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
CA2654523A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
US20080008743A1 (en) * 2006-07-06 2008-01-10 Forest Laboratories Holdings Limited Orally Dissolving Formulations of Memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
RU2485949C2 (ru) 2007-04-11 2013-06-27 Фармасьютикал Продакшнс Инк Таблетка мелатонина и способы изготовления и применения
WO2008128095A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RU2394571C1 (ru) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Способ лечения воспалительных заболеваний кишечника
RU2418586C2 (ru) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой
RU2428183C1 (ru) 2010-07-01 2011-09-10 Рина Михайловна Заславская Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204259A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Child and Adolescent Psychopharmacology. 16(5), 제517-524쪽(2006.10.)*

Also Published As

Publication number Publication date
AU2012380583B2 (en) 2015-01-22
UA112352C2 (uk) 2016-08-25
JP2015517569A (ja) 2015-06-22
WO2013176567A1 (ru) 2013-11-28
EA201400973A1 (ru) 2015-02-27
EP2857011A4 (en) 2015-12-02
JP5864819B2 (ja) 2016-02-17
IL235852A0 (en) 2015-01-29
EP2857011A1 (en) 2015-04-08
IN2014DN09940A (https=) 2015-08-14
KR20150005999A (ko) 2015-01-15
US20150157604A1 (en) 2015-06-11
CA2873891C (en) 2016-02-16
CA2873891A1 (en) 2013-11-28
HK1205467A1 (en) 2015-12-18
AU2012380583A1 (en) 2014-12-18
CN104334166A (zh) 2015-02-04
RU2488388C1 (ru) 2013-07-27

Similar Documents

Publication Publication Date Title
KR101581611B1 (ko) 정신, 행동, 인지 장애의 예방 및 치료용 약학적 조성물
US12138242B1 (en) Controlling neuropathic pain
US20110281929A1 (en) Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
US20220096491A1 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
CN115776885A (zh) 用于治疗阿尔茨海默病和帕金森病的组合物和方法
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
CN112957334B (zh) 含alpelisib的药物组合物
CN103520147B (zh) 葛根素或含有葛根素的药物组合物在制备具有预防或治疗老年痴呆症作用的药物中的用途
WO2015060746A1 (ru) Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза
US9999614B2 (en) Combination for the prophylaxis and treatment of behavioural, mental, and cognitive disorders
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
EP4070793A1 (en) Pharmaceutical composition, complementary kit and application thereof
CN111939139A (zh) 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法
WO2025186837A1 (en) A synergistic bioactive composition for controlling neuromuscular pain and repairing nerve damage
US20040176463A1 (en) Immediate release formulation of n-(2-propylpentanoyl)glycinamide
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
TR202019859A1 (tr) Emoksi̇pi̇n ve donepezi̇l i̇çeren farmasöti̇k formülasyonlar
CN121079083A (zh) 高强度单单位剂量制剂和其使用方法
KR20180101539A (ko) 수면장애를 예방 및 치료하기 위한 약제학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141124

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141210

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20141210

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150319

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150811

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20151215

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
EXTG Ip right invalidated
PC2102 Extinguishment

Termination category: Others

Termination date: 20161019